logo
Low-dose X-ray treatment is being used for arthritis, plantar fasciitis and other benign conditions

Low-dose X-ray treatment is being used for arthritis, plantar fasciitis and other benign conditions

Washington Post2 days ago
In March 2024, radiation oncologist Sanjay Mehta had been dealing with painful Achilles tendinitis on his left ankle for over a year. He'd tried steroid injections and PRP (platelet-rich plasma) injections, which Mehta said eventually did the trick.
But when his right Achilles started hurting three months later, he opted for a different approach. He had recently started offering low-dose radiation therapy to treat some patients suffering from inflammatory conditions and thought: Why not try it himself? After six self-administered low-dose X-rays, covered by insurance, he found he was pain-free — and he began offering the therapy to more patients with similar noncancerous conditions.
'The main surprise was … why didn't I think of this earlier?' he said.
Mehta is part of a growing trend among U.S. radiation specialists, who have begun offering low-dose X-ray therapy for benign conditions such as arthritis, plantar fasciitis, Peyronie's disease and thick raised scars, or keloids.
After the American Society for Radiation Oncology discussed the use of low-dose radiation therapy for nonmalignant conditions in its spring 2024 quarterly newsletter, its use began to pick up steam, Mehta said. Unlike radiation therapy for cancer, LDRT, as its name suggests, uses low doses to suppress inflammatory cells. Mehta said six LDRT treatments expose the patient to about the same amount of radiation as in one cancer treatment or what someone might get from 'a few' CT scans.
Low-dose radiation treatments almost date back to when X-rays were first discovered in 1895, Mehta said. They eventually fell out of favor in part due to new treatment options, such as nonsteroidal anti-inflammatory drugs, but also because of radiation fears, he said.
Gopal Bajaj, the musculoskeletal lead for the American Society for Radiation Oncology task force on non-oncologic disease, said LDRT remained popular in Europe. The German Society for Radiation Oncology published national guidelines for its use in nonmalignant diseases in 2000. In the United States, 'it's within the last decade or so that there's been a slow reemergence of interest into exploring radiotherapy for conditions other than cancer,' Bajaj said.
Bajaj first encountered it as a therapy about a decade ago when an interested patient with Dupuytren's contracture — a condition that involves thickening of the skin on the palm of the hand, often causing fingers to curl under — asked for it. He started delving into the scientific literature, which was primarily German, and decided it was worth a try. It worked, halting the progression of her condition, which Bajaj said is the goal of the treatment. Since then, Bajaj has seen around 800 people with the disease who fly in from all over the country.
'Most patients we see with Dupuytren's are actively progressing when they begin treatment, and after radiation therapy, fewer than 5 to 8 percent continue to worsen,' Bajaj said. When it comes to inflammatory conditions like osteoarthritis, tendinopathy or plantar fasciitis, Bajaj said, 60 to 80 percent of his patients report some symptom improvement.
A Department of Veterans Affairs survey last year of 48 studies on the effectiveness of LDRT for a variety of conditions, some several decades old, found mixed evidence to make conclusions about its effectiveness, but it said there was no reason not to try it 'after conventional therapy fails.' Bajaj and Mehta said they believe the research is still catching up to what doctors are seeing in the clinical setting.
Whenever there's trauma (from a surgery or an injury), macrophages, white blood cells that modulate inflammation, begin to secrete chemicals that promote inflammation. The X-rays suppress the macrophages, which 'stops this inflammatory cascade from taking hold and, therefore, the pain and the swelling goes away,' Mehta said.
LDRT can work for injuries or conditions where there's inflammation, Mehta said, such as tendinitis, osteoarthritis and plantar fasciitis.
In some cases, LDRT seems to provide immediate relief, while others can take longer. In Mehta's case, it took six to eight weeks before his Achilles felt better. A cortisone shot may work faster, he said, but judging from his and his patients' experiences, the LDRT results seem to last longer. He said it may also be more beneficial to the long-term health of the joints because cortisone shots can weaken the tendon and the fibers of the connective tissue, which can up the risk for tendon ruptures with repeated injections.
There is a 'sweet spot' for LDRT, Bajaj said. If a patient's condition is too advanced, such as if their arthritis has led to a bone-on-bone (without cartilage or fluid to pad it) situation, or there's an autoimmune component to it, such as with ankylosing spondylitis, it probably won't work, he said.
Not all radiation specialists are on board with low-dose X-ray treatment for benign conditions. At Moffitt Cancer Center in Florida, for instance, when Jose Penagaricano, a radiation oncologist who has been treating patients with malignant conditions for six years, started treating osteoarthritis and Dupuytren contracture about a year ago, he got some pushback from colleagues worried that LDRT would take machine time away from ill cancer patients, he said. By limiting consultations for LDRT cases, though, he said the impact has been minimal.
The bigger concern that those using LDRT have heard from colleagues and patients is radiation exposure. Even low-dose exposure over a lifetime has the potential to cause a small increase in the risk of cancer, according to the Environmental Protection Agency.
David Brenner, director of the Center for Radiological Research at the Columbia University Vagelos College of Physicians and Surgeons, said that, in general, the long-term health concerns related to radiation exposure are specific to organs that 'have a lot of dividing cells,' such as the gastrointestinal system. Hands, feet and knees — frequent sites for LDRT — would be of less concern, he said.
A 2015 study in the British Journal of Radiology suggests that the risks of cancer following low-dose radiation therapy for benign disease tend to be small, especially in older patients. But because 'exposure to radiation has the potential to cause a radiation-induced cancer many years after treatment,' it may be an issue for younger adults, adolescents and children, the study said. Concerns about lifetime accumulation of radiation is why radiation doctors typically use this treatment only on patients over 40, Mehta said.
'The major thing people are worried about with radiation is radiation itself causing cancer, [but] it takes, even in higher-dose cancer patients, literally decades for a second cancer to develop,' he said. 'With these low doses of radiation that we use for arthritis and tendinitis, there's been nothing described in the literature for over a hundred years.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dr. Javad Sajan Does First Facial-Feminization with Simultaneous Hair Transplant Procedure
Dr. Javad Sajan Does First Facial-Feminization with Simultaneous Hair Transplant Procedure

Yahoo

time15 minutes ago

  • Yahoo

Dr. Javad Sajan Does First Facial-Feminization with Simultaneous Hair Transplant Procedure

Seattle Plastic Surgeon Performs Nation's First Combined Facial Feminization & Hair Transplant Surgery SEATTLE, WA / / August 5, 2025 / Dr. Javad Sajan, a top Seattle plastic surgeon and founder of Allure Esthetic Plastic Surgery, has made medical history in the U.S. by performing the nation's first facial feminization surgery (FFS) combined with hair transplant in a single operative session. The milestone procedure was performed on Ember Norman and is featured on offering a detailed look at the surgical planning, technique, and outcomes. The entire surgery, including the hair transplant, qualified for coverage under Norman's gender‑affirming insurance plan. As part of a full facial feminization surgery, Dr. Javad Sajan performed a carefully planned combination of skeletal and soft tissue procedures to transform the patient's facial structure and features. The surgery began with upper facial bone contouring, including frontal bone and orbital bone reduction, and a frontal sinus setback to soften and feminize the upper third of the face. A follicular unit transplant of 1,000 grafts was performed to feminize the hairline. To further feminize the upper face, Dr. Sajan performed a brow lift, elevating the brow position for a more open and feminine expression. In the midface, a mid-facelift and rhinoplasty were performed to enhance facial harmony and refine nasal shape and projection. For the lower face, Dr. Sajan completed a lip lift to shorten the philtrum and improve lip aesthetics. This was followed by chin bone reduction and jaw bone reduction to narrow and sculpt the lower facial contour. This comprehensive transformation reflects the precision and artistry involved in advanced facial feminization surgery. The full surgical journey and before-and-after results can be viewed here. These combined procedures eliminate the need for a second surgery, making the healing process easier and more efficient. Key benefits of this approach include: Single anesthesia event and one recovery timeline A lower and more feminine hairline Minimal scarring Who is an ideal candidate for a same-day FFS+ hair transplant? Ideal candidates for simultaneous FFS and hair transplant surgery include healthy transgender or non-binary patients who are medically cleared for general anesthesia, have realistic expectations, and maintain stable hormone levels for at least six months. Is combining the procedures safe? Combining both procedures in a single session is generally safe; however, all surgery and anesthesia have risks. It eliminates the need for a second anesthesia event, minimizes cumulative swelling, and avoids re-entering previously operated areas, such as a freshly feminized forehead, during a later surgery. How long does the surgery take? The combined procedure typically takes 6 to 12 hours, depending on the extent of facial bone reshaping and the number of hair grafts required. About Dr. Javad Sajan and Allure Esthetic Plastic Surgery: Dr. Javad Sajan is a renowned Seattle-based plastic surgeon, known for his leadership in gender-affirming and facial cosmetic surgery. At Allure Esthetic, Dr. Sajan and his team blend advanced techniques with personalized care to deliver exceptional results. Media Contact:Allure Esthetic Plastic SurgeryPhone: 206-209-0988Website: info@ SOURCE: RealDrSeattle View the original press release on ACCESS Newswire Sign in to access your portfolio

Why Hims & Hers Health Stock Just Dropped
Why Hims & Hers Health Stock Just Dropped

Yahoo

time15 minutes ago

  • Yahoo

Why Hims & Hers Health Stock Just Dropped

Key Points Hims & Hers Health stock missed on earnings last night. The company grew sales 73% and profits tripled, but Wall Street wanted more. Hims & Hers also reported negative free cash flow for the first half of the year. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS), the telehealth company famous for selling Ozempic lookalikes over the internet, is tumbling today, down 6.7% through 10:55 a.m. ET after missing in its second-quarter earnings report last night, on both the top and bottom lines. Heading into the report, analysts forecast Hims & Hers would earn $0.23 per share on $552 million in sales -- but Hims & Hers earned only $0.17 per share, and sales were less than $545 million. Hims & Hers' Q2 earnings But was the news really as bad as it seems? After all, while Hims & Hers "missed" on sales, it did still grow sales 73% year over year. That was twice as fast as it grew subscribers, too (31%), indicating that not only are more customers signing up for the company's services, but they're buying more, too. And while Hims & Hers missed on earnings, too, those earnings per share nearly tripled year over year. Really, the only "bad" number I see in the report concerns free cash flow (FCF). Through the first half of this year, Hims & Hers grew its operating cash flow only 13%, to $90 million (within a couple of percentage points of reported net income). However, the company spent massively on capital expenditures -- more than $100 million -- resulting in negative FCF for the first half of 2025. Investors seem unsure what to make of the news. At one point this morning, the stock had recovered all its losses, and even turned green, before falling back into the red. Is Hims & Hers stock a sell? So how should investors react to this conflicting news? At $13.6 billion in market capitalization, Hims & Hers stock costs a pricey 70 times trailing earnings. It's even more expensive when valued on FCF -- about 103 times. These might be acceptable valuations if earnings were to continue tripling year after year. In fact, though, analysts see profits growing only 13% this year, and perhaps 57% next. For the time being, Hims & Hers stock remains too expensive to buy. Should you buy stock in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $631,505!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,103,313!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Rich Smith has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool has a disclosure policy. Why Hims & Hers Health Stock Just Dropped was originally published by The Motley Fool

Multiple infections linked to raw milk consumption in Florida, health officials say
Multiple infections linked to raw milk consumption in Florida, health officials say

Yahoo

time15 minutes ago

  • Yahoo

Multiple infections linked to raw milk consumption in Florida, health officials say

The Florida Department of Health is investigating an outbreak of infections linked to drinking unpasteurized milk, officials said this week. The health department issued a bulletin Monday, reporting that 21 people who consumed raw milk from the same farm had been infected with campylobacter and E. coli, with seven of those patients requiring hospitalization. Of the 21 cases, six were children under the age of 10. "Severe complications have been reported for at least two cases," officials said. The health department did not name the farm that produced the raw milk but confirmed the ingredient was linked to the cases. It is illegal to sell raw milk for human consumption in Florida. Raw milk can legally be sold for non-human consumption "as pet or animal food," the health department stated, because it doesn't undergo the same sanitary regulations and can be a source of foodborne illness. "Due to continued recent cases of Campylobacter and Shiga toxin-producing E. coli (STEC) infections linked to a particular farm, the Florida Department of Health is providing information to assist Floridians in making informed decisions about their health," Monday's health alert stated. "Sanitation practices in this farm are of particular concern due to the number of cases." This is a developing story. Please check back for more details. Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store